One Health approach to a new treatment for acute pancreatitis in people and dogs
Official title: One Health Advancement of RABI-767 for the Management of Acute Pancreatitis
Funded at Lamassu Pharma INC. · NIH-11360137 · Data updated 2026-11-12
A new drug, RABI-767, is being developed to treat acute pancreatitis in both humans and dogs, aiming to prevent organ failure.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lamassu Pharma INC. NIH-funded |
| Lab location | 1 site (Durham, UNITED STATES) |
| Project start | July 7, 2020 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $865,872 |
| NIH project number | 5R44DK125219-05 |
| Project ID | NIH-11360137 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are dogs with spontaneous acute pancreatitis and adults at risk for severe acute pancreatitis who may participate in subsequent human trials.
✕Less likely to help
Patients with pancreatitis due to non-lipase pathways or those unable to receive lipase-inhibiting therapies may not benefit.
What this research studies
This project aims to develop a novel therapy for acute pancreatitis, addressing an unmet medical need in humans and veterinary medicine. It focuses on blocking lipase activity to reduce lipolysis and lipotoxicity, which can worsen the disease. The plan includes companion animal (dog) studies to test different dosing schedules and to gather data to guide a future human trial. The team combines clinical, translational, and veterinary expertise and has IND-enabling safety data in dogs and rats. The work envisions advancing toward a phase 2 human study based on canine results.
Why it matters
Potential benefit: If successful, patients with acute pancreatitis could receive a new treatment that reduces the progression to severe disease and organ failure, potentially shortening recovery time.
How similar studies have gone: Preclinical data and prior models show that inhibiting lipase activity can reduce organ failure and systemic inflammation in pancreatitis, supporting this approach.
Where this research is happening
-
Lamassu Pharma INC.
Durham, United States Active
Researchers
- Principal investigator: Hanna, Gabi — Lamassu Pharma INC.
- Study coordinator: Hanna, Gabi
Related research
Other NIH-funded projects on the same topics.
-
Diabetes after acute pancreatitis: understanding and tracking progression
A patient-focused look at how diabetes can develop after an episode of acute pancreatitis, using data from a large, ongoing study and AI insights.
-
Continuation of Type 1 Diabetes in Acute Pancreatitis: UF Health and AdventHealth
A patient-facing overview of a long-term study tracking people with acute pancreatitis to understand how some develop type 1 diabetes later and what factors influence that process.
-
Data Coordinating Center for Type 1 Diabetes in Acute Pancreatitis Consortium
A national effort to learn how pancreatitis-related Type 1 diabetes develops, by tracking patients and coordinating data to improve future care.
-
Diabetes after acute pancreatitis: a patient-focused network study
A program at Indiana University is studying how diabetes can develop after an acute pancreatitis episode, with new findings that could help doctors tailor care for adults who had pancreatitis.
-
Type 1 Diabetes in Acute Pancreatitis in Diabetes Patients at Stanford
A Stanford-led project helps people with brittle type 1 diabetes who also experience pancreatitis by following them in a long-term study to understand how acute pancreatitis affects diabetes.
-
Epidemiology and causes of diabetes after acute pancreatitis
A long-term study following people who have had acute pancreatitis to understand how often diabetes develops, why it happens, and how it progresses.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.